Grant H. Skrepnek, Ph.D., R.Ph.

Professor

Pharmacy Clinical & Admin Sci

Phone (405) 271-6878 x47105

Fax (4050 271-6430

Office CPB 214

Email grant-skrepnek@ouhsc.edu


Summary

I concentrate on health economics, policy, and outcomes research involving large-scale database investigations, decision analyses, clinical trials, and survey research. From a clinical stance, I focus on studying cost, quality, and access to care across various healthcare settings concerning oncology, cardiopulmonary disease, rare conditions, and comorbidities. I am engaged in advancing the methodological approaches used within assessments of health technology, including the development of novel statistical procedures to evaluate health and economic data.



Research

Dr. Skrepnek concentrates on health economics, policy, and outcomes research involving large-scale database investigations, decision analyses, clinical trials, and survey research. From a clinical stance, Dr. Skrepnek focuses on studying cost, quality, and access to care across various healthcare settings concerning oncology, cardiopulmonary disease, rare conditions, and comorbidities. He is engaged in advancing the methodological approaches used within assessments of health technology, including the development of novel statistical procedures to evaluate health and economic data.




Publications & Presentations

<< 4 5 6 7 8 9 10 > >>
    31. Pham T T, Skrepnek G H, Bond C, Alfieri T, Cothran T J, Keast S. Overview of Prescription Opioid Deaths in the Oklahoma State Medicaid Population, 2012-2016. Medical Care. 2018; 56 : 727-735

    32. Pham T T, Keast S, Farmer K, Thompson D M, Rathbun C, Nesser N J, Holderread B P, Skrepnek G H. Sustained virologic response and costs associated with direct-acting antivirals for chronic hepatitis C infection in Oklahoma Medicaid. Journal of Managed Care and Specialty Pharmacy. 2018; 24 : 664-676

    33. Pham T, Rathbun C, Keast S, Nesser N, Farmer K, Skrepnek G H. National estimates of case-mix, mortality, and economic outcomes among inpatient HIV/AIDS mono-infection and hepatitis C co-infection cases in the US. Journal of Evaluation in Clinical Practice . 2018

    34. Fox A, Skrepnek G H, Miller J L, Schwier N C, Ripley T L. Optimal Medical Therapy Prescribing Patterns and Disparities Identified in Patients with Acute Coronary Syndromes at an Academic Medical Center in an Area with High Coronary Heart Disease-Related Mortality. American Journal of Cardiovascular Drugs . 2018

    35. Combs D, Skrepnek G H, Seckeler M D, Barber B J, Morgan W J, Parthasarathy S. Sleep-disordered breathing is associated with increased mortality in hospitalized infants with congenital heart disease. Journal of Clinical Sleep Medicine. 2018; 14 : 1551-1558

<< 4 5 6 7 8 9 10 > >>



Grants

1 2 3 4 >>
    1. [Cooperative Agreement] Oklahoma State Department of Health, A Strategic Approach to Advancing Health Equity for Priority Populations with or at Risk for Diabetes – 2023 (DP-23-0020, FAIN #NU58DP007376, CFDA #93.988 (Cooperative Agreements for State-Based Diabetes Control Programs and Evaluation of Surveillance Systems). . CDC. Start Date: 2023. End Date: 2024.

    2. [Cooperative Agreement] Oklahoma State Department of Health, Chronic Disease Prevention Program: The National Cardiovascular Health Program (DP-23-0004, FAIN #NU58DP007471, CFDA #93.426 - The National Cardiovascular Health Program, CDV/Heart. CDC. Start Date: 2023. End Date: 2024.

    3. HIV Adherence Services. Start Date: 2022. End Date: 2023.

    4. Patterns of Care, Outcomes, and Barriers to Treatment Success or Vaccination Associated with Adult Community-Acquired Pneumonia in Medicaid. Misc Non-Federal. Start Date: 2021. End Date: 2022.

    5. [Service Agreement] Opioid Use Under Oklahoma Senate Bill 848.. Non-federal. Start Date: 2020. End Date: 2020.

1 2 3 4 >>



Awards and Honors


no results

Education


no results